Related Experiment Video
Updated: May 21, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Glycemic Outcomes and Device Engagement Over 18 Months Following Initiation of Two Different Automated Insulin
Jayde Hooven-Davis1, Ingrid Libman1, Scott D Rothenberger2
1Division of Pediatric Endocrinology, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Objective:
We compared long-term, real-world glycemic outcomes and device engagement in U.S. youth with type 1 diabetes (T1D) using two automated insulin delivery (AID) systems.
Methods:
We included youth (ages 6-18) with T1D from a large academic center who started on Insulet Omnipod 5 (OP5) or Tandem Control IQ (CIQ) between January 2020 and June 2024. We collected 30-day continuous glucose monitor and 30-day AID data at baseline and 3, 6, 12, and 18 months following AID initiation. We evaluated change in glycemic metrics and user behaviors (e.g., self-initiated bolusing and carbohydrate entry) by system using separate multivariable linear regression models at each time point while adjusting for baseline factors (age, sex, insulin regimen prior to AID initiation, diabetes duration, and baseline values for the respective glycemic metric).
Results:
All AID users (n = 722, median age 14.3 years, median diabetes duration 5.5 years, 83.9% previous pump users) had a significant change in time in range (TIR) across all time points (>9.9% increase). While CIQ users (n = 311) experienced a greater change in TIR at 3 and 6 months (+14.9% and +13.3%, respectively, vs. +10.0% and +10.2% among OP5 users), this difference waned with time (change in TIR at 18 months +9.9% with CIQ vs. +10.6% with OP5). Carbohydrate entry simultaneously decreased at the same intervals among CIQ users (199, 184, and 173 g at 3, 6, and 18 months, respectively) but not OP5 users (177, 184, and 181 g at 3, 6, and 18 months).
Conclusions:
Although glycemic outcomes are similar between devices over 18 months, AID user engagement changes with time and differs between systems, potentially as they "trust" their device more. Change in carbohydrate entry among CIQ users is likely a major contributor to the decline in TIR with longer duration of AID use.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology